AstraZeneca succeeds in treating late-stage lupus in new study

The drugmaker AstraZeneca said on Monday its experimental treatment significantly reduced disease activity in patients with the autoimmune disorder lupus in a late-stage study.

Scroll to continue with content
Ad

What to Read Next